1. Home
  2. UVV vs GLUE Comparison

UVV vs GLUE Comparison

Compare UVV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$58.65

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$19.37

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
GLUE
Founded
1886
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UVV
GLUE
Price
$58.65
$19.37
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$29.50
AVG Volume (30 Days)
175.8K
2.7M
Earning Date
02-09-2026
03-19-2026
Dividend Yield
5.58%
N/A
EPS Growth
N/A
N/A
EPS
4.44
0.25
Revenue
$2,987,411,000.00
$181,538,000.00
Revenue This Year
$3.21
$84.02
Revenue Next Year
$1.02
N/A
P/E Ratio
$13.24
$77.41
Revenue Growth
3.01
1112.27
52 Week Low
$49.96
$3.50
52 Week High
$67.33
$25.77

Technical Indicators

Market Signals
Indicator
UVV
GLUE
Relative Strength Index (RSI) 76.72 44.37
Support Level $53.63 $19.91
Resistance Level $56.20 $21.69
Average True Range (ATR) 0.93 1.39
MACD 0.37 -0.63
Stochastic Oscillator 90.14 8.72

Price Performance

Historical Comparison
UVV
GLUE

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: